BioNTech SE (BNTX)
BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript
BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript
BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push
The company said it would exit operations at some manufacturing plants in Germany and Singapore, as well as sites it acquired as part of its CureVac takeover.
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains?
BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Two experimental drugs showed striking early results against pancreatic cancer
Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.
BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript
BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript
One simple reason why BioNTech stock is a raging buy on today's crash
BioNTech (NASDAQ: BNTX) swung to a Q4 loss and guided for “lower-than-expected” full-year revenue on Tuesday. But the stock crashed more than 20%, mostly because its cofounders, Ugur Sahin (CEO) and Ozlem Tureci (CMO), said they would depart to set up a new biotech firm at the end of 2026.
BioNTech co-founders set to launch new mRNA venture as company sharpens oncology focus
BioNTech SE (NASDAQ:BNTX) co-founders Ugur Sahin and Özlem Türeci plan to launch a new independent biotech company focused on next-generation mRNA technologies, the German vaccine developer said on Tuesday, as it intensifies its focus on oncology. BioNTech said it will contribute certain related rights and technologies to the new venture in exchange for a minority stake, with potential milestone payments and royalties.
Scientists behind COVID-19 vaccine will depart BioNTech
The company's co-founders said they are leaving to start a new mRNA-based company.
BioNTech Cofounders to Leave to Form New Company
The company said its cofounders were leaving to form a biotechnology startup focused on developing messenger RNA.
BioNTech: The Market Is Pricing Low Oncology Success
BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. At a $27.6B market cap and ~$11B enterprise value, BNTX's pipeline—including Pumitamig, ADCs, and mRNA vaccines—is valued conservatively by the market. Scenario analysis shows downside is cushioned by cash, while upside hinges on pivotal oncology data over the next 12–18 months.
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock?
BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
